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Summary
Background. — Very late thrombosis of drug eluting stents is a rare complication that might be
triggered by resistance to platelet antiaggregants (PAAs). 
Aim. — Following an initial case where clinical data strongly suggested resistance to PAAs, we
carried out a prospective systematic analysis of platelet aggregation in four subsequent cases
of late thrombosis. 
Methods. — Resistance to aspirin was investigated with the PFA-100 test employing a collagen-
epinephrine cartridge (Platelet Function Analyzer; Dade Behring). Resistance to clopidogrel
was determined by flow cytometry of intraplatelet vasodilator-stimulated phosphoprotein
(VASP) phosphorylation. 
Results. — All four cases showed resistance to either aspirin or clopidogrel, and two cases
showed dual resistance to both of these PAAs.
Conclusion. — Analysis of platelet function in a patient with late stent thrombosis is useful and
may allow adaptation of subsequent patient management. The value of monitoring platelet
function after implantation of a drug eluting stent should be evaluated in prospective studies. 
© 2008 Published by Elsevier Masson SAS.
Résumé
Justification. — La thrombose très tardive est une complication rare des stents actifs pour
laquelle la résistance aux antiagrégants plaquettaire (AAP) pourrait être un facteur favorisant. 
Objectifs. — Suite à un premier cas évoquant fortement une résistance aux AAP uniquement sur
des données cliniques, nous avons réalisé de façon prospective pour les quatre thromboses très
tardives suivantes une analyse systématique de l’agrégation plaquettaire. 
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Méthodes. — La résistance à l’aspirine a été recherchée par le test PFA-100 utilisant une
cartouche collagène-épinéphrine (Platelet Function Analyser, Dade Behring) et la résistance au
clopidogrel par l’étude en cytométrie en flux de la phosphorylation de la protéine intra
plaquettaire vasodilatator-stimulated phosphoprotein (VASP). 
Résultats. — Sur les quatre cas, tous présentent au moins une résistance à l’aspirine ou au
clopidogrel et deux d’entre eux, une double résistance aux AAP. 
Conclusion. — L’analyse de la fonction plaquettaire chez un patient ayant présenté une
thrombose tardive de stent est intéressante, et pourrait permettre d’adapter la prise en charge
ultérieure. Sa place après implantation d’un stent actif mérite d’être évaluée par des études
prospectives 
© 2008 Published by Elsevier Masson SAS.
Introduction
Late thrombosis of stents eluting active substances (active
stents) is a rare complication, which is nevertheless devas-
tating for patients. As with bare stents several groups of
factors that can trigger thrombosis have been identified
including those linked to the implantation procedure, those
linked to the patient, and those linked to the stent itself
[1]. However, where active stents in particular are concer-
ned platelet antiaggregant (PAA) treatment appears to play
an important role, especially premature discontinuation of
PAAs [2]. Resistance of a patient to the action of a PAA
(aspirin or clopidogrel) has been described as another fac-
tor leading to thrombosis [3,4]. 
In this report, we describe five cases of very late thrombo-
sis, occurring between 12 and 54 months after stent implan-
tation, where resistance to PAAs, suggested strongly in the
first case from the patient’s medical history, was confirmed
in the four subsequent cases by performing platelet function
tests used for the evaluation of primary hemostasis. 
Patients and methods
Following an initial case of very late stent thrombosis for
which anamnesis strongly suggested resistance to PAAs, we
carried out a prospective systematic analysis of platelet
aggregation in subsequent cases. Four patients were inves-
tigated over a period of 15 months. In order to verify good
patient compliance before stent thrombosis, an interview
was carried out according to the method of Girerd et al.
[5]. Blood samples were also taken 6±1 days after the
thrombosis, when the combination of aspirin (160 mg/day)
and clopidogrel (75 mg/day, preceded by a loading dose of
300–600 mg) had been reinitiated in these patients. 
Resistance to aspirin was determined with the PFA-100
test using collagen and epinephrine (Platelet Function Ana-
lyzer; Dade Behring) and measurement of occlusion time
(OT), where an OT of <190 sec indicates resistance to aspi-
rin [6]. Resistance to clopidogrel was investigated by flow
cytometry of intraplatelet vasodilator-stimulated phospho-
protein (VASP) phosphorylation, which enabled the deter-
mination of an index of platelet reactivity (IPR), an IPR of
>50% indicating resistance to clopidogrel. Among the nume-
rous platelet agonists, ADP plays a major role via interme-
diary P2Y12 receptors. Clopidogrel selectively and irrever-
sibly inhibits the pathway of activation of the P2Y12
receptor by ADP and thus blocks ADP-dependant activation
of platelets. VASP phosphorylation is one of the steps in
P2Y12 receptor pathway.
Case observations
Case n°1
In August 2004, a 75-year-old patient with a history of chro-
nic obstructive bronchitis and arteriopathy obstructing the
lower limbs, and cardiovascular risk factors of smoking,
excess weight and hereditary heart disease (Table 1), pre-
sented with anterior myocardial infarction complicated by
sudden death and was resuscitated from inaugural ventricu-
lar fibrillation. The patient received intravenous thrombo-
lysis following reperfusion criteria. Clinical evolution was
uncomplicated: CPK peaked at 4800 IU/l (normal = 0–155IU/l)
and transthoracic echography demonstrated a left ventricu-
lar ejection fraction (LVEF) of 45% with a large anteroseptal
akinesia. Coronarography, carried out on the 8th day revea-
led a long and tight stenosis in the proximal left anterior
decending artery (LAD) with TIMI 3 flow below. A short and
dense stenosis was also present in the right coronary artery
(RCA). A double angioplasty by direct stenting was carried
out in the LAD (sirolimus stent; Cypher®, 3.0 x 18 mm, 11
atm) and RCA (bare stent; Driver®, 4.0 x 15 mm, 10 atm),
with an excellent angiographic outcome. The patient then
underwent cardiovascular reeducation with treatment com-
bining clopidogrel (75 mg/day), aspirin (75 mg/day), perin-
dopril (8 mg/day), simvastatin (40 mg/day), furosemide
(40 mg/day), and then bisoprolol (2.5 mg/day). The combi-
nation of clopidogrel plus aspirin was continued for
15 months, and then monotherapy with clopidogrel was
continued for 6 months. In the 19th month post-angioplasty,
clopidogrel treatment was replaced by monotherapy with
aspirin (75 mg/day). Eleven days later, the patient presen-
ted with signs of infarction including thoracic pain and ECG
revealed ST-segment elevation in inferior leads with ante-
rior mirroring, and first degree AV block. Thrombolysis with
streptokinase was initiated but was ineffective; the patient
deteriorated hemodynamically and was transferred to our
center in a state of cardiogenic shock. Immediate coronaro-
graphy demonstrated thrombosis of the sirolimus stent in
the LAD as well as a thrombosis of the bare stent in the
RCA, with TIMI 0 flow in the two lesions. Despite initiation
of mechanical dethrombosis by thrombo-aspiration with the
Export® system, insertion of a bare stent in the RCA (Dri-
ver®, 4.0 x 30 mm, 12 atm) and dethrombosis of the stent
in the LAD, orotracheal intubation, insertion of an intraaor-
tic balloon pump and a probe for electrosystolic training,
the patient died from electromechanical dissociation.
Résistance 
à l’aspirine ;
Résistance
au clopidogrel.
102 G. Barone-Rochette et al.
Case n°2
In 2003, an 80-year-old man with dyslipidemia (LDL: 1.65g/l)
presented symptoms of effort angina, with positive exer-
cise stress test (table 1). Coronarography demonstrated the
existence of bitruncular lesions with tight stenosis of the
LAD (figure 1A) and long stenosis of the second segment of
the RCA. On the 25th November 2003 angiography was car-
ried out and sirolimus stents were implanted in the LAD
(Cypher® 3.0 x 23 mm, 12 atm) (figure 1B) and RCA in C2
(Cypher® 3.0 x 23 mm, 12 atm) with an excellent angiogra-
phic result. Fifty minutes after angiography the patient pre-
sented with thoracic pain and ST-segment elevation from
V1 to V3. An emergency coronarography was carried out
and demonstrated an acute LAD intrastent thrombosis with
TIMI 2 flow below (figure 1C). Mechanical dethrombosis by
balloon angioplasty (VIVA$, 3.0 x 20 mm, 12 atm) under
abciximab enabled restoration of normal coronary flow and
disappearance of the thoracic pain and ST-elevation
(figure 1D). Follow-up was uncomplicated with a CPK peak
of 400IU/l. The patient left hospital on clopidogrel (150 mg/
day for 5 days then 75 mg/day), aspirin (75 mg/day), biso-
prolol (5 mg/day), perindopril (4 mg/day) and simvastatin
(40 mg/day). On the 5th August 2005 (21 months later) the
patient was seen by his cardiologist for his annual check up
where it was decided to stop combined therapy with clopi-
dogrel and aspirin in favor of monotherapy with aspirin
alone. On the 11th August 2006, more than 32 months after
the angioplasty procedure and 12 months after discontinua-
tion of clopidogrel, the patient presented with thoracic
pain. ECG performed during transport noted a course of
infarction of the anterior myocardium. The patient unde-
rwent pre-hospitalization fibrinolysis and was rapidly trans-
ferred to the interventional cardiology room. During trans-
port the thoracic pain persisted and the ECG changed with
extension of ST-segment elevation in the inferior territory.
Coronarography demonstrated a double acute thrombosis
on the active stents in the LAD (figure 2A) and RCA with
TIMI 0 flow below the two lesions (figure 2B). Rescue bal-
loon angioplasty resulted in deobstruction of the two stents
with TIMI 3 flow at the end of the procedure; it was noted
that simple passage of the guide in the LAD restored TIMI 3
flow without the appearance of stenosis instead of throm-
bosis (figure 2C and 2D). During the procedure the hemody-
namic and rhythmologic state of the patient was unstable,
requiring the insertion of a probe for electrosystolic trai-
ning and an intraaortic balloon pump. The evolution of the
hemodynamic and rhythmic state enabled removal of the
intraaortic balloon pump and electrosystolic training probe
on day +2. The CPK peak was 3000 IU/l. Echography demos-
trated a LVEF of 35%, a large anterosepto-apical hypokinesia
Table 1 Clinical characteristics of the five cases of very late stent thrombosis.
Case Age
(years)
CVRF Localization 
and type
 of stents 
implanted
Stents with 
thrombosis
Time of 
very late 
thrombosis 
(months)
Treatment 
before the 
thrombosis
Immediate
mangement 
of 
thrombosis
Treatment 
after the 
thrombosis
1 75 Smoking
Excess 
weight
Hereditary
LAD - Cypher
RCA - Driver
LAD - Cypher
RCA - Driver
19 Aspirin 
75 mg
Aspirin 250 mg IV + 
clopidogrel 300 mg
trombosis + rescue 
angioplasty
Patient died
2 80 Dyslipide-
mia
LAD - Cypher
RCA - Cypher
LAD - Cypher
RCA - Cypher
33 Aspirin 
75 mg
Aspirin 250 mg IV then 
160 mg per os +
clopidogrel 600 mg 
then 75 mg + abciximab
primary angioplasty
Aspirin 75 mg 
+ clopidogrel 
150 mg
3 78 Dyslipide-
mia
AHT
Smoking
LAD - Titan
LAD - Taxus
LAD - Taxus 29 Aspirin 
75 mg + 
clopido-
grel 75 mg
Aspirin 250 mg IV then 
160 mg per os +
clopidogrel 600 mg 
then 75 mg + abciximab
primary angioplasty
Elective by 
pass + aspirin 
160 mg
4 52 0 Proximal LAD 
- Cypher
Distal LAD - 
Vision + 
Cypher
Proximal 
LAD - Cypher
12 Aspirin 
75 mg
Aspirin 250 mg IV then 
60 mg per os +
clopidogrel 600 mg 
then 75 mg + abciximab
primary angioplasty
Elective by 
pass + 
clopidogrel 
75 mg
5 50 AHT LAD - Driver
LAD - Cypher
Proximal 
LAD - Cypher
48 0 Aspirin 250 mg IV then 
160 mg per os +
clopidogrel 600 mg 
then 75 mg + abciximab
primary angioplasty
Aspirin 160 mg 
+  clopidogrel 
150 mg
CVRF: cardiovascular risk factors.
AHT: Arterial hypertension.
RCA: right coronary artery.
LAD: left anterior decending artery.
Cypher and Taxus: active stents.
Driver, Titan and Vision: bare stents.
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with hyperkinesia of the other walls. No problem with com-
pliance was found. The results of blood tests supported a
good response to aspirin but biological resistance to clopi-
dogrel, with TO > 300 sec and an IPR of 74% (table 2). After
medico-surgical discussion it was decided to increase the
dose of clopidogrel (150 mg/day). The patient left our ser-
vice for a center of cardiovascular reeducation on clopido-
grel (150 mg/day), aspirin (75 mg/day), bisoprolol (5 mg/
day), perindopril (4 mg/day) and simvastatin (40 mg/day).
A control IPR was carried out several months later: this new
test revealed an IPR of 48%. Subsequent evolution was
uncomplicated over a period of 9 months. 
Case n° 3
A 78-year-old man with dyslipidemia (LDL: 1.55 g/l) and a
history of smoking and hypertension was hospitalized on the
18th August 2003 for coronography in the context of effort
angina with positive exercise stress test (table 1). This
revealed a monotruncular lesion of the proximal LAD.
Direct stenting was carried out with a bare stent (Titan®,
3.5 x 16 mm, 10atm); an excellent angiographic result was
obtained at the end of the procedure. At the beginning of
2004 effort angina reoccurred with positive proof of effort.
Coronarography demonstrated a dense restenosis at the
entrance to the stent. Direct stenting with insertion of an
active stent (Taxus®, 12 x 3.5 mm, 10 atm) was carried out
on 26th May 2004 with an excellent result. On the 11th Octo-
ber 2006, 29 months after insertion of the Taxus stent, the
patient presented with signs of infarction including thoracic
pain and antero-lateral ST-segment elevation on ECG.
Immediate coronarography demonstrated an acute throm-
bosis at the entrance of the proximal LAD stent with TIMI 0
flow and also significant stenosis at the level of the second
and start of the third segment of the RCA. The insertion of
a bare stent in the proximal LAD (Vision, 3.0 x 8 mm, 12
atm) followed by thrombo-aspiration using the Export® sys-
tem under abciximab enabled restoration of TIMI 3 flow. An
intraaortic balloon pump was inserted due to the appearance
of signs of left ventricular insufficiency at the end of the
procedure. Hemodynamic evolution was favorable despite a
CPK peak of 8.135IU/l. Echography revealed a LVEF of 40%
with large anteroseptal-apical hypokinesia. The patient was
Figure 1. A. Significant stenosis of the left anterior decending artery in patient n°2 (for clinical history see text). B. The same patient
after implantation of a sirolimus stent in the left anterior decending artery. C. Emergency coronarography showing an acute intrastent
thrombosis in the left anterior decending artery, 50 min after the initial procedure. D. Mechanical dethrombosis and balloon angioplasty.
1A 1B
1C 1D
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questioned about his treatment before the acute event; this
had consisted of clopidogrel (75 mg/day), aspirin (75 mg/day),
felodipine (10 mg/day) and simvastatin (40 mg/day). There
was no evidence of poor compliance by the patient. Tests
for resistance to AAPs suggested biological resistance to
both aspirin and clopidogrel, with a TO of 153 sec in the
PFA-100 test with collagen-epinephrine and an IPR of 94%
with the VASP test (table 2). The patient was sent for myo-
cardial revascularization by aorto-coronary bypass in view
of the tritruncular lesions and particularly the three endo-
prostheses in the proximal LAD. Evolution at 7 months was
uncomplicated. 
Case n°4
A 52-year-old patient, without any known risk factor, pre-
sented in September 2005 with infarction in the anterior
myocardium and received pre-hospitalization fibrinolysis at
Figure 2. A. The same patient as figure 1 with very late thrombosis (33 months) of a sirolimus stent implanted in the left anterior decen-
ding artery.  B. Very late thrombosis associated with a sirolimus stent implanted in the right coronary artery. C. After balloon angioplasty
of the left anterior decending artery. D. After balloon angioplasty of the right coronary artery.
2A 2B
2C 2D
Table 2 Results of platelet aggregation tests.
PFA-100 VASP
Case 1 Not performed Not performed
Case 2 >300 sec 74%
Case 3 153 sec 94%
Case 4 88 sec 41%
Case 5 133 sec 58%
PFA: platelet-function analyzer.
VASP: vasodilator-stimulated phosphoprotein phosphorylation
Biological resistance to aspirin: TO < 190 sec with aspirin 
(PFA-100).
Biological resistance to clopidogrel: IRP > 50% with clopidogrel 
(VASP).
Very late stent thrombosis and resistance to antiaggregants 105
h +4 (table 1). Emergency coronarography demonstrated an
old occlusion of the RCA at the end of the second segment
and two dense stenoses in the proximal and distal LAD, with
TIMI 1 flow below. The rest of the reservoir was atheroma-
tous without significant stenosis. Angioplasty of the proxi-
mal LAD was carried out with an active stent (Cypher®, 2.75
x 13 mm, 16 atm) associated with dethrombosis and com-
plementary double angioplasty in the distal LAD (bare
stent; Vision®, 2.5 x 12 mm, 16 atm, and active stent
(Cypher®, 2.5 x 8 mm, 15 atm). TIMI 3 flow was obtained at
the end of the procedure without residual stenosis. Follow-
up was straightforward with a CPK peak of 1.200IU/l and a
LVEF of 51% with anterior hypokinesia and apical akinesia
on echography. Treatment on discharge comprised aspirin
(75 mg/day), clopidogrel (75 mg/day), ramipril (10 mg/
day), fluvastatin (20 mg/day) and acebutolol (200 mg/day).
In September 2006, 12 months later, it was decided to stop
clopidogrel. Thirty days later, the patient presented with
signs of infarction with thoracic pain and ST-segment eleva-
tion from C1 to C3 on ECG. Coronarography revealed throm-
bosis of the active stent in the proximal LAD, associated
with tritruncular lesions. Dethrombosis under abciximab
was carried out by thrombo-aspiration with the Export® sys-
tem, restoring TIMI 3 flow at the end of the procedure. Fol-
low-up was normal, echography revealed a LVEF of 45%
with anterosepto-apical hypokinesia and a CPK peak of
6.000IU/l. Tests for resistance to AAPs were carried out
after establishing good compliance by the patient, and
demonstrated biological resistance to aspirin with a TO of
88 sec and the absence of clopidogrel resistance with an
IPR of 41% (table 2). A decision was made to perform an
aorto-coronary bypass within a period of 3 weeks in view of
the tritruncular lesions. Subsequent evolution was uncom-
plicated over a period of 7 months.
Case n°5
A 50-year-old female with treated hypertension had an
inert stent inserted into the proximal LAD following an
acute coronary syndrome. Six-months later, an active siro-
limus stent was implanted due to intrastent restenosis
(Cypher®, 3.0 x 23mm, 12 atm) (table 1). In April 2007,
4 years after implantation of the active stent, and after
carrying out myocardial perfusion scintigraphy, which was
normal, it was decided to stop clopidogrel 5 days before
breast reduction surgery. Immediately after surgery, the
patient presented with thoracic pain and ST-segment eleva-
tion and required transfer to our unit for emergency coro-
narography. This revealed an intra-stent thrombosis in the
LAD with TIMI 0 flow below. Dethrombosis was carried out
at the same time, first by thrombo-aspiration with the Export®
system and then by balloon dilation (Viva®, 3 x 20 mm, 6 atm)
with restoration of TIMI 3 flow at the end of the procedure.
Follow-up was straightforward, echography revealed a LVEF
of 55% with anterior akinesia and a CPK peak of 4800 IU/l.
The results of AAP resistance tests supported biological
resistance to aspirin, with a TO of 133 sec, as well as to clo-
pidogrel, with an IPR of 58% (table 2). The patient left our
unit on treatment with aspirin (160 mg/day), clopidogrel
(150 mg/day), atorvastatin (80 mg/day), pantoprazole
(40 mg/day), celiprolol (200 mg/day), trandolapril (2 mg/day),
and trinitrine on demand. The immediate evolution was
marked by multiple episodes of ventricular tachycardia
requiring implantation of an implantable defibrillator. The
6 months follow up was uncomplicated. 
Discussion
The availability of active stents has drastically reduced the
incidence of restenosis by neointimal hyperplasia without
increasing the risk of thrombosis (early) in pivotal randomi-
zed trials [7,8]. Thrombosis of active stents is a rare com-
plication with an incidence of 0.4–1% [9,10,11], but is
nevertheless a devastating event leading to myocardial
infarction in three out of four cases and death in 25–45% of
patients [12,13]. The frequency of late thrombosis (repor-
ted up to 4 years) is estimated to be between 0.52% and
1.2% depending on the more or less restrictive definition of
thrombosis and the population studied (in randomized
trials) [14,15] or registered [12,16]. After 12 months, the
term very late stent thrombosis is used [17]. However,
while the rate of acute and subacute thrombosis (<30 days)
is identical after insertion of an active stent or a bare stent
[18], controversy exists about the higher risk of late throm-
bosis (>30 days), or very late thrombosis. The randomized
BASKET-LATE study compared the evolution of patients who
had received bare stents (Vision®) or active stents (Cypher®
or Taxus®). The patients were treated for 6 months with
clopidogrel plus aspirin, and then followed for 12 months
after discontinuation of dual therapy. This study demons-
trated a significantly higher number of cases of non-fatal
infarction or cardiovascular death in the group implanted
with active stents (4.9% versus 1.3%, p < 0.01) [19]. Never-
theless, this was a limited series of patients and recent
meta-analyses of randomized trials, comparing either siro-
limus stents with bare stents [14,15,20,21], or paclitaxel
stents with bare stents [20], did not find any increase in
overall risk of thrombosis in the 4 years, but suggested a
moderate but significant increase in very late thrombosis.
This increased risk can be explained by the delay in endo-
thelialization of active stents compare to bare stents [22].
Discontinuation of AAP treatment or the premature discon-
tinuation of the clopidogrel-aspirin combination are the
most important factors favoring stent thrombosis [9],
before reendothelialization of the stent is achieved. This is
the principal mechanism proposed by McFadden et al. [2]. 
While the recommendations concerning the duration of
dual AAP treatment are clear after insertion of an inert
stent (at least 1 month after implantation), those concer-
ning implantation of an active stent remain unclear. Whe-
reas the value of continuing the combination well beyond
the 3 or 6 months in current recommendations in patients
with active stents is clear, prolongation of treatment
beyond 1 year remains controversial. 
Resistance of a patient to the action of AAPs is another
major risk factor for thrombosis. Some studies have
demonstrated an increase in number of cardiovascular
events associated with resistance to aspirin in patients
treated for stable or instable angina [23-25]. Matetzky et
al. [26] and Baragan et al. [3] reported an identical pheno-
menon in the case of resistance to clopidogrel. The preva-
lence of resistance to AAPs varies according to different
studies. It is estimated that the desired antiaggregant
effect is not obtained in 5-45% of patients taking aspirin and
in 4-30% of those taking clopidogrel. This large variation in
prevalence can be explained by the use of different
methods for the analysis of platelet function and by a lack
of standardization of techniques between laboratories [27].
Aggregometry is the most widely used technique for the
analysis of platelet reactivity. However, this technique is
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not widely available, is long and difficult to standardize,
suffers from poor reproducibility and is difficult to inter-
pret [28]. Progress in our knowledge of the mode of action
of antiaggregants has enabled the development of new
tests. The analysis of intraplatelet VASP phosphorylation by
flow cytometry has been standardized and is reproducible
[29], making it a valuable test in cardiology for the detec-
tion of resistance to clopidogrel. Barragan et al. noted that
63% of patients presenting with stent thrombosis were
resistant to clopidogrel versus 40% in the group without
stent thrombosis (p < 0.0001). The variability in biological
response over time in the same patient may be a limitation
to the predictive value of this test for clinical events. 
The PFA-100 system (Dade-Behring) is used to measure
adhesion and platelet aggregation under conditions of high
shear-stress conditions in a manner close to in vivo measu-
rement of bleeding time [30]. The time necessary to obtain
a stop in flow is called the occlusion time (OT) and depends
on platelet function. This is a rapid test that is easy to carry
out [31]. Resistance to aspirin can be demonstrated by the
PFA-100 test with collagen-epinephrine [32]. Few prospec-
tive studies have been carried out on the prognostic value
of the PFA-100 test post-angioplasty. Gianetti et al. [33]
evaluated platelet function using the PAF-100 test, 30 ± 8 h
after angioplasty in 175 patients hospitalized either for sta-
ble angina (n = 94), or for acute coronary syndrome
(n = 81). After follow-up for 6 months, the risk of relapse of
coronary events determined by multivariate analysis was
greatly increased in the group with an OT of < 190 sec in the
PFA-100 collagen-epinephrine test. 
No prospective study to date, however, has demonstra-
ted the relevance of these tests to predict stent thrombosis
and learned Societies do not recommend the prospective
and systematic use of these tests [34]. Finally, in a prospec-
tive study of a group of 804 patients, Buonanici et al. [35]
demonstrated that the rate of appearance of stent throm-
bosis was three times higher among the 13% of patients who
were resistant to clopidogrel (8.6% vs. 2.3%). 
Our series of five cases of very late stent thrombosis
occurred over a period of 15 months from April 2003 when
725 active stents were implanted by our team (an incidence
of 0.6%/year). The implication of resistance to AAPs is illus-
trated by our five clinical cases. The first case strongly sug-
gested resistance to aspirin from anamnesic data although
analysis of platelet function was not carried out. The
patient, who was protected from thrombosis for several
months by monotherapy with clopidogrel, developed late
thrombosis on an active stent but also concomitant late
thrombosis on a bare stent after several days of treatment
with aspirin. Our second case was original and revealed a
double very late thrombosis of sirolimus stents more than
32 months after implantation and 1 year after stopping dual
therapy. Above all, this highlights the persistent risk of
thrombosis long-term in implanted patients. It should be
noted that increasing the dose of clopidogrel in this patient
with biological resistance was successful at overcoming the
resistance. However, the clinical relevance of this observa-
tion, namely proof of a reduction in active stent thrombosis
secondary to this dose modification, has not been demons-
trated at present. The third case demonstrated very late
thrombosis of a paclitaxel stent. Dual resistance was
demonstrated while the patient was on combined AAP the-
rapy. Such patients have a high risk of cardiovascular
events [27], highlighting the potential importance of loo-
king for dual resistance. What alternative therapy can be
proposed for these patients? After collegial discussion,
aorto-coronary bypass was recommended. The fourth case
revealed very late thrombosis of an active sirolimus stent in
a patient on aspirin monotherapy. This patient presented
biological resistance to aspirin but not to clopidogrel. Thus
we can assume from these data that the patient would be
better protected by monotherapy with clopidogrel. This
fourth case also underlines the potential value of looking
for resistance to antiaggregants when changing from bi- to
monotherapy. The final case demonstrates thrombosis of an
active stent 4 years after its implantation, but 6 days after
stopping clopidogrel for surgery. This patient also presen-
ted dual resistance to aspirin and clopidogrel. It should be
noted that this patient, like patient 3, had been treated by
implantation of an active stent for restenosis of a bare
stent. Although this indication is currently approved
because it has been shown to be effective against the
appearance of new restenosis [36], we cannot formerly rule
out the possibility that it increases the risk of stent throm-
bosis. 
In our cases, the first emergency procedure was mecha-
nical deobstruction with a loading dose of AAP + anti-GPII-
bIIIa (type: abciximab). During dethrombosis the following
steps in patient management should be followed: first,
patient compliance must be established. If this is not in
question, platelet aggregation tests should be carried out.
In the case of resistance, management is not clear and
depends on the area at risk, the result of emergency inter-
ventional procedure carried out, and the presence of other
known risk factors for thrombosis. Heart surgery may be
proposed in a patient with a high risk of rethrombosis or
with a large area at risk. If this is not the case, combined
AAP treatment should be continued, doubling the dose of
clopidogrel, and rechecking the platelet function tests
under the modified doses.
In conclusion, the cases presented here show that analy-
sis of platelet function is of value in patients suffering from
stent thrombosis, but may also be useful clinically when
applied prospectively, in particular in patients with a high
risk of thrombosis. These tests may provide vital informa-
tion about the management of AAP treatment in these
patients. However, there is currently no consensus on the
nature of the tests or which tests to carry out. Randomized,
prospective studies demonstrating a correlation between
the diagnosis of biological resistance and the subsequent
appearance of thrombosis are necessary. 
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